Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GOT1 | P17174 | 6/20 | 0.65 |
| ▸ | MEN1 | O00255 | 6/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.57 |
| ▸ | STING1 | Q86WV6 | 2/20 | 0.53 |
| ▸ | MAPT | P10636 | 6/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | FPR2 | P25090 | 1/20 | 0.52 |
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 1/20 | 0.49 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | IDO1 | P14902 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26086655 | 0.87 | GOT1 (0.61) | GOT1MEN1KMT2ASTING1MAPT | |
| SCHEMBL26088517 | 0.82 | GOT1 (0.67) | GOT1MEN1KMT2ASTING1MAPT | |
| SCHEMBL23925541 | 0.81 | GOT1 (0.79) | GOT1MEN1KMT2ASTING1MAPT | |
| SCHEMBL26086523 | 0.75 | MEN1 (0.58) | GOT1MEN1KMT2ASTING1MAPT | |
| SCHEMBL29176616 | 0.75 | CFTR (0.58) | MEN1KMT2ASTING1 | |
| SCHEMBL1852082 | 0.74 | MEN1 (0.73) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL734585 | 0.73 | MEN1 (1.00) | GOT1MEN1KMT2AMAPTSMN1; SMN2 | |
| SCHEMBL23925488 | 0.72 | MEN1 (0.82) | MEN1KMT2ATRPV1 | |
| SCHEMBL22446343 | 0.72 | LMNA (0.63) | MEN1KMT2AMAPTSMN1; SMN2LMNA | |
| SCHEMBL1850096 | 0.72 | KMT2A (0.59) | MEN1KMT2AMAPTSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC | 2023-04-27 | — | — | US | claimed |
| WO-2021211123-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-10-21 | — | — | WO | claimed |
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC | 2023-04-27 | — | — | US | disclosed |
| WO-2021211123-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | UNIVERSITY OF NOTRE DAME DU LAC (US) | 2021-10-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230131376-A1 | ADJUVANT-ANTIBIOTIC COMBINATION AGAINST GRAM-NEGATIVE BACTERIA | TLR4, TLR5, TLR1 | GOT1 871/4885MEN1 2778/4885KMT2A 2581/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.